Bumetanide considered effective in the treatment of genetic Alzheimer's by the end of 2026?
Sağlık ve TıpOne-Off1ay
FutuurKullanılabilirliği kontrol etDoğrulanmış sonuçlanma verisiGüncel ima edilen olasılık
Hayır 93%
Hayır 93%Piyasa kalitesi
31 / 100
Düşük kalite24s Hacim
—
Likidite
₺12,8 B
Düşük likiditeİşlemciler
9
Yorumlar
1
Piyasa verileri
1 dakika önce güncellendi
Trendler
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
Will cold showers be shown to be an effective treatment for depression by 2030
Manifold MarketsMeasles cases in U.S. in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketWill a pneumonic plague case be reported in the U.S. this year?
KalshiNew pandemic in 2026?
PolymarketWill the FDA approve retatrutide?
KalshiKurallar
Drug repositioning is a common technique in research, where drugs that have already been approved to treat a certain disease are used to treat different diseases.
- By cross-referencing information from various sources, scientists in the United States have arrived at a drug that might be repositioned to treat Alzheimer's disease in patients with genetic mutations that increase the risk of developing the disease.
- According to their studies, Bumetanide - a diuretic drug - managed to reduce learning deficits in mice, and showed positive effects in human neurons in vitro.
- The next step was to analyze the medical records of more than 5 million adult patients, which led to the observation that the development of Alzheimer's disease was lower among those who made use of the diuretic drug.
- Despite the encouraging news, more tests are still needed to validate such a hypothesis.
- The next step for researchers will be to conduct randomized clinical trials to demonstrate the efficacy of bumetanide against genetic Alzheimer's disease.